tl;dr: Anthropic's life sciences team has partnered with six drug companies (including BMS, Generate Biomedicines, and BigHat) to apply Claude across drug development tasks—from molecule design and antibody generation to manufacturing paperwork and clinical trial planning—with reported wins like 35,000 antibody designs in a month, 89% reduction in document review time, and regulatory drafts cut from months to hours. Anthropic also acquired Mithril Medicine, a one-person muscular dystrophy startup, and aims to have a Claude-assisted drug candidate in human trials by late 2028. Most work remains preclinical.